XCRT Quote, Financials, Valuation and Earnings

Cryo-Cell International, Inc. has a net margin of -- compared to Xcelerate, Inc.'s net margin of 9.58%. Xcelerate, Inc.'s return on equity of -- beat Cryo-Cell International, Inc.'s return on equity of --.

Xcelerate, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Cryo-Cell International, Inc. has an analysts' consensus of $8.50 which suggests that it could grow by 147.1%. Given that Cryo-Cell International, Inc. has higher upside potential than Xcelerate, Inc., analysts believe Cryo-Cell International, Inc. is more attractive than Xcelerate, Inc..

Xcelerate, Inc. has a beta of 0.778, which suggesting that the stock is 22.154% less volatile than S&P 500. In comparison Cryo-Cell International, Inc. has a beta of 0.689, suggesting its less volatile than the S&P 500 by 31.12%.

Xcelerate, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cryo-Cell International, Inc. offers a yield of 18.9% to investors and pays a quarterly dividend of $0.15 per share. Xcelerate, Inc. pays -- of its earnings as a dividend. Cryo-Cell International, Inc. pays out 510.2% of its earnings as a dividend.

Xcelerate, Inc. quarterly revenues are $535.4K, which are smaller than Cryo-Cell International, Inc. quarterly revenues of $7.8M. Xcelerate, Inc.'s net income of -$229K is lower than Cryo-Cell International, Inc.'s net income of $749.4K. Notably, Xcelerate, Inc.'s price-to-earnings ratio is -- while Cryo-Cell International, Inc.'s PE ratio is 498.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xcelerate, Inc. is 3.33x versus 0.88x for Cryo-Cell International, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

National HealthCare Corp. has a net margin of -- compared to Xcelerate, Inc.'s net margin of 10.77%. Xcelerate, Inc.'s return on equity of -- beat National HealthCare Corp.'s return on equity of 10.22%.

Xcelerate, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand National HealthCare Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that Xcelerate, Inc. has higher upside potential than National HealthCare Corp., analysts believe Xcelerate, Inc. is more attractive than National HealthCare Corp..

Xcelerate, Inc. has a beta of 0.778, which suggesting that the stock is 22.154% less volatile than S&P 500. In comparison National HealthCare Corp. has a beta of 0.645, suggesting its less volatile than the S&P 500 by 35.519%.

Xcelerate, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. National HealthCare Corp. offers a yield of 1.85% to investors and pays a quarterly dividend of $0.64 per share. Xcelerate, Inc. pays -- of its earnings as a dividend. National HealthCare Corp. pays out 37.04% of its earnings as a dividend. National HealthCare Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Xcelerate, Inc. quarterly revenues are $535.4K, which are smaller than National HealthCare Corp. quarterly revenues of $380.8M. Xcelerate, Inc.'s net income of -$229K is lower than National HealthCare Corp.'s net income of $41M. Notably, Xcelerate, Inc.'s price-to-earnings ratio is -- while National HealthCare Corp.'s PE ratio is 21.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xcelerate, Inc. is 3.33x versus 1.43x for National HealthCare Corp.. Usually stocks with elevated PS ratios are considered overvalued.

SRx Health Solutions, Inc. has a net margin of -- compared to Xcelerate, Inc.'s net margin of -13.47%. Xcelerate, Inc.'s return on equity of -- beat SRx Health Solutions, Inc.'s return on equity of --.

Xcelerate, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand SRx Health Solutions, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Xcelerate, Inc. has higher upside potential than SRx Health Solutions, Inc., analysts believe Xcelerate, Inc. is more attractive than SRx Health Solutions, Inc..

Xcelerate, Inc. has a beta of 0.778, which suggesting that the stock is 22.154% less volatile than S&P 500. In comparison SRx Health Solutions, Inc. has a beta of 0.882, suggesting its less volatile than the S&P 500 by 11.819%.

Xcelerate, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SRx Health Solutions, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xcelerate, Inc. pays -- of its earnings as a dividend. SRx Health Solutions, Inc. pays out -- of its earnings as a dividend.

Xcelerate, Inc. quarterly revenues are $535.4K, which are smaller than SRx Health Solutions, Inc. quarterly revenues of $7.2M. Xcelerate, Inc.'s net income of -$229K is higher than SRx Health Solutions, Inc.'s net income of -$964K. Notably, Xcelerate, Inc.'s price-to-earnings ratio is -- while SRx Health Solutions, Inc.'s PE ratio is 0.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xcelerate, Inc. is 3.33x versus 0.04x for SRx Health Solutions, Inc.. Usually stocks with elevated PS ratios are considered overvalued.